228 related articles for article (PubMed ID: 23002203)
1. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.
Hantschel O; Grebien F; Superti-Furga G
Cancer Res; 2012 Oct; 72(19):4890-5. PubMed ID: 23002203
[TBL] [Abstract][Full Text] [Related]
2. Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Gray NS; Fabbro D
Methods Enzymol; 2014; 548():173-88. PubMed ID: 25399646
[TBL] [Abstract][Full Text] [Related]
3. Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase.
Johnson TK; Bochar DA; Vandecan NM; Furtado J; Agius MP; Phadke S; Soellner MB
Angew Chem Int Ed Engl; 2021 Sep; 60(37):20196-20199. PubMed ID: 34292655
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
5. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS
J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site.
Dong J; Lu W; Pan X; Su P; Shi Y; Wang J; Zhang J
Bioorg Med Chem; 2014 Dec; 22(24):6876-84. PubMed ID: 25464886
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
8. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.
Mian AA; Metodieva A; Badura S; Khateb M; Ruimi N; Najajreh Y; Ottmann OG; Mahajna J; Ruthardt M
BMC Cancer; 2012 Sep; 12():411. PubMed ID: 22985168
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.
Liu J; Zhang Y; Huang H; Lei X; Tang G; Cao X; Peng J
Chem Biol Drug Des; 2021 Mar; 97(3):649-664. PubMed ID: 33034143
[TBL] [Abstract][Full Text] [Related]
10. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.
Preyer M; Vigneri P; Wang JY
PLoS One; 2011 Feb; 6(2):e17020. PubMed ID: 21347248
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
Skaggs BJ; Gorre ME; Ryvkin A; Burgess MR; Xie Y; Han Y; Komisopoulou E; Brown LM; Loo JA; Landaw EM; Sawyers CL; Graeber TG
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19466-71. PubMed ID: 17164333
[TBL] [Abstract][Full Text] [Related]
12. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms.
Schenone S; Brullo C; Botta M
Curr Med Chem; 2010; 17(13):1220-45. PubMed ID: 20166937
[TBL] [Abstract][Full Text] [Related]
13. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
[TBL] [Abstract][Full Text] [Related]
14. Detection of allosteric kinase inhibitors by displacement of active site probes.
Lebakken CS; Reichling LJ; Ellefson JM; Riddle SM
J Biomol Screen; 2012 Jul; 17(6):813-21. PubMed ID: 22453235
[TBL] [Abstract][Full Text] [Related]
15. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M
Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617
[TBL] [Abstract][Full Text] [Related]
16. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of flavone-based inhibitors of wild-type and T315I mutant of ABL.
Choe H; Kim J; Hong S
Bioorg Med Chem Lett; 2013 Aug; 23(15):4324-7. PubMed ID: 23790540
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
19. Insight into the allosteric inhibition of Abl kinase.
Fallacara AL; Tintori C; Radi M; Schenone S; Botta M
J Chem Inf Model; 2014 May; 54(5):1325-38. PubMed ID: 24787133
[TBL] [Abstract][Full Text] [Related]
20. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Griswold IJ; MacPartlin M; Bumm T; Goss VL; O'Hare T; Lee KA; Corbin AS; Stoffregen EP; Smith C; Johnson K; Moseson EM; Wood LJ; Polakiewicz RD; Druker BJ; Deininger MW
Mol Cell Biol; 2006 Aug; 26(16):6082-93. PubMed ID: 16880519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
